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Abstract
Background: Despite the fact that metastases are the leading cause of colorectal cancer deaths,
little is known about the underlying molecular changes in these advanced disease stages. Few have
studied the overall gene expression levels in metastases from colorectal carcinomas, and so far,
none has investigated the peritoneal carcinomatoses by use of DNA microarrays. Therefore, the
aim of the present study is to investigate and compare the gene expression patterns of primary
carcinomas (n = 18), liver metastases (n = 4), and carcinomatoses (n = 4), relative to normal
samples from the large bowel.
Results: Transcriptome profiles of colorectal cancer metastases independent of tumor site, as well
as separate profiles associated with primary carcinomas, liver metastases, or peritoneal
carcinomatoses, were assessed by use of Bayesian statistics. Gains of chromosome arm 5p are
common in peritoneal carcinomatoses and several candidate genes (including PTGER4, SKP2, and
ZNF622) mapping to this region were overexpressed in the tumors. Expression signatures stratified
on TP53 mutation status were identified across all tumors regardless of stage. Furthermore, the
gene expression levels for the in vivo tumors were compared with an in vitro model consisting of
cell lines representing all three tumor stages established from one patient.
Conclusion: By statistical analysis of gene expression data from primary colorectal carcinomas,
liver metastases, and carcinomatoses, we are able to identify genetic patterns associated with the
different stages of tumorigenesis.
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Colorectal cancer (CRC) is the second most common
cause of cancer related deaths in developed countries,
including Norway [1,2]. Despite the fact that metastases
are the leading cause of colorectal cancer deaths, the
majority of genetic studies of colorectal carcinogenesis
have focused on changes found in primary carcinomas,
and the knowledge about the underlying molecular
changes in more advanced disease stages remain limited.
To obtain insights to this process, identification of molec-
ular key events that distinguish primary from metastatic
tumors is important. DNA microarray technology has
become powerful for whole-genome investigations [3].
Recently, several reports have shown that results obtained
by this technology can distinguish among subgroups of
the same cancer tissue [4-7] as well as among different
cancer types [8]. Additionally, genetic profiles have been
identified that predict patients' clinical outcome in can-
cers of the breast, lung, central nervous system, digestive
system, and prostate [9-15]. Several studies has investi-
gated the expression profile of primary colorectal carcino-
mas [16]. However, only a few have investigated the gene
profiles of lymph node and liver metastases derived from
colorectal carcinomas [17-24], and so far none have stud-
ied metastasis to the peritoneal cavity by DNA microar-
rays. Whereas previous reports have focused only on the
comparisons between normal mucosa and primary carci-
nomas, or primary carcinomas and metastases, we aimed
to investigate the relationship between the primary carci-
nomas and metastases regardless of site, as well as the
genetic patterns that might distinguish the different meta-
static sites from each other. Therefore, we have analyzed
the gene expression profiles of normal colon, primary car-
cinomas, liver metastases and peritoneal metastases, as
well as an in vitro model of CRC progression by oligo
microarrays, to compare the genetic patterns from the dif-
ferent stages of the colorectal tumorigenesis.
Results
Gene expression pattern in metastases versus those of 
primary tumors
In order to find a gene expression pattern that distin-
guishes metastatic tumors from primary carcinomas, dif-
ferentially expressed genes between metastases
independent of site and primary carcinomas were identi-
fied. BAMarray [25] was used with a posterior variance
between 0.92 and 1.06. The hundred most statistically sig-
nificant genes associated with metastases (n = 8, liver
metastases and carcinomatoses) and primary carcinomas
(n = 18) were chosen, with a Z-cut absolute values ranged
from 4.41 to 2.84 for metastases and 3.77 to 2.32 for pri-
mary carcinomas. Among these genes, 89 were expressed
more than two-fold differently between the groups
(twenty of these more than three-fold). Forty of the 89
genes were associated with the metastasis group, and thus,
49 with the primary group [see Additional file 1]. By using
the 89 genes found from BAMarray, primary carcinomas
and liver metastases were distinguished by hierarchical
clustering (Figure 1). Liver metastases and carcinomatoses
were intermingled, with the exception of one liver metas-
tasis (76L) that is seen as an outlier compared to the rest
of the metastases group. The gene expression profiles of
three primary carcinomas (984P, 1029P, and 1296P) that
later developed metastases did not show any similarity
with each other or with the metastasis group when clus-
tered on these selected genes. To find differentially
expressed genes that distinguish the two metastatic sites
from each other, as wells as from primary carcinomas, the
dataset was grouped into primary carcinomas, liver metas-
tases and carcinomatoses and further analyzed by BAMar-
ray. A posterior variance between 0.93 and 1.19 were
chosen, providing 51 genes associated with carcinoma-
toses, with absolute Z-cut from 3.59 to 2.30. Twenty-nine
of these 51 genes were expressed more than two-fold com-
pared to normal mucosa (Table 2). For primary carcino-
mas and liver metastases the hundred most statistically
significant genes for each group derived from BAMarray
were chosen, with absolute Z-cut at 4.15 to 2.95 for liver
metastases, and 3.79 to 2.40 for primary carcinomas. Alto-
gether, 251 differentially expressed genes from the three
different tumor stages were chosen, and 53 of these genes
revealed an expression level above three-fold in the
median of the tumor stages (17 genes were associated
with primary carcinomas, 28 with liver metastases, and
eight with carcinomatoses), and among these, 23 genes
were expressed above four-fold. To visualize the difference
of the most statistically significant genes associated with
each tumor site we performed PCA and HCA on the 53
genes derived from primary carcinomas, liver metastases,
and carcinomatoses with expression above three-fold
(Figure 2). The PCA plot distinguishes the three tumor
stages from each other based on this gene list, except for
one liver metastasis (2L) that shows a closer association to
the carcinomatoses than to the other tumors (Figure 2A).
These results were confirmed by HCA, where the dendro-
gram distinguishes seven out of the eight metastatic
tumors from all of the primary carcinomas (Figure 2B).
Three of four liver metastases clustered together, while 2L
clustered in close association with the carcinomatoses as
seen by PCA. One carcinomatosis (64C) appeared alone.
We did not find a specific expression pattern of any of the
genes in the selected gene list within the primary carci-
noma group stratified by localization, Dukes' status, TP53
mutation status, or recurrence.
Genes located to chromosome arm 5p were of particular
interest, as we have previously identified gain of 5p to be
important for the CRCs' ability to metastasize to the peri-
toneal cavity [26]. Among the 115 genes at 5p in the data-
set, 20 genes were more than two-fold higher expressed in
carcinomatoses, as compared to liver metastases and pri-
mary carcinomas (Table 3).Page 2 of 16
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Table 1: Clinicopathological information.
Tumor Tumor ID Dukes' stagea TP53 mutation statusb Sexc Aged
primary carcinomas 923P C wildtype M 85
974P B ex8, c273, CGT→CAT, Arg→His M 73
980P C wildtype F 75
984P C wildtype F 88
988P B wildtype F 66
1029P C wildtype M 83
1069P B wildtype M 74
887P B wildtype F 82
927P B ex6, c190, CCT→CTT, Pro→Leu F 73
953P B ex6, 5 bp insertion; c216–217: GTG GTG to GTGgtggtGTG M 68
976P B wildtype M 58
1027P B ex7, c241–242, TCCTGC→TTCCGC, Ser-Cys→Phe-Arg M 79
868P B wildtype M 64
904P B ex8, c272, CTG→ATG, Val→Met M 78
912P B wildtype F 66
941P B ex8, c282, CGG→TGG, Arg→Trp M 78
1276P B wildtype M 79
1296P B ex7, c244, GGC→GTC, Gly→Val M 76
liver metastases 136L D ex5, c132, AAG→AGG, Lys→Arg M 68
81L D wildtype M 74
2L C wildtype M 75
76L D ex7, c241, TCC→TC, 1 bp deletion M 55
carcinomatoses 98C D wildtype M 72
1C D wildtype F 62
17C C ex5, c175, CGC→CAC, Arg→His F 67
64C D wildtype M 40
aDukes' stage of the primary tumors, and the primary tumor of liver metastases and carcinomatoses. bex, exon; c, codon; bp, base pair. cM, male; F, 
female. dAge at diagnosis.
Dendrogram from differentially expressed genes between metastases and primary tumorsFigure 1
Dendrogram from differentially expressed genes between metastases and primary tumors. Dendrogram from 
hierarchical clustering of the 89 most statistical differentially expressed genes between metastases (n = 8; carcinomatoses and 
liver metastases together indicated in red) and primary carcinomas (n = 18 indicated in black), with a more than two-fold 
change derived from BAMarray.
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Table 2: Genes (n = 29) associated with colorectal carcinomatoses as compared to primary tumors and liver metastases.
Genebank Acc. Gene Symbol Gene Name Z-cut Fold change liver Fold change carcinomatoses Fold change primary Relative difference, 
carcinomatosis vs. primary
BC035498 CCNE1 cyclin E1 -3,59 -1.51 -2.15 1.05 2.24
AB011124 ProSAPiP1 ProSAPiP1 protein 3,24 1.37 2.26 1.28 1.77
NM_022772 EPS8L2 EPS8-like 2 -3,16 -1.64 -2.28 1.29 1.74
AK025824 EPS8L2 EPS8-like 2 -3,12 -1.63 -2.12 1.22 1.74
BC005245 C1orf41 chromosome 1 open reading frame 41 -3,07 -1.40 -2.63 -1.35 1.88
NM_017515 SLC35F2 solute carrier family 35, member F2 -2,89 -1.48 -2.75 -1.31 1.08
U73778 COL12A1 collagen, type XII, alpha 1 2,85 -1.72 2.34 1.15 1.77
BC004260 CAPN10 calpain 10 -2,85 4.54 -4.09 -2.34 2.03
NM_033018 PCTK1 PCTAIRE protein kinase 1 2,84 1.88 2.51 1.50 1.66
AK096896 ASB12 ankyrin repeat and SOCS box-containing 12 2,82 1.68 2.00 1.70 1.18
NM_033254 BOC brother of CDO 2,81 1.26 2.09 1.30 1.61
NM_018043 TMEM16A transmembrane protein 16A 2,78 -1.92 2.68 -1.84 5.08
BC012915 MPRP-1 metalloprotease related protein 1 -2,76 -1.70 -2.18 -1.57 1.39
BC002728 THRA thyroid hormone receptor, alpha (erythroblastic 
leukemia viral (v-erb-a) oncogene homolog, avian)
-2,73 -1.41 -2.15 -1.23 1.73
X06482 HBQ1 hemoglobin, theta 1 2,71 1.69 2.61 1.28 2.09
X78947 CTGF connective tissue growth factor 2,65 2.32 3.94 1.85 2.22
AF067817 VAV3 vav 3 oncogene -2,63 -1.79 -2.50 -1.29 4.14
U86602 EBNA1BP2 EBNA1 binding protein 2 -2,63 -1.19 -4.81 -1.16 1.94
AL834404 NETO2 neuropilin (NRP) and tolloid (TLL)-like 2 -2,59 -1.96 -4.33 -1.47 2.93
M94065 DHODH dihydroorotate dehydrogenase -2,58 -1.63 -2.17 -1.04 2.08
NM_025109 MYOHD1 myosin head domain containing 1 -2,57 -1.68 -2.65 -1.03 2.55
NM_016234 ACSL5 acyl-CoA synthetase long-chain family member 5 -2,52 -2.52 -3.51 -1.52 2.07
NM_005132 REC8L1 REC8-like 1 (yeast) -2,50 -1.41 -2.15 -1.11 1.19
NM_003412 ZIC1 Zic family member 1 (odd-paired homolog, 
Drosophila)
2,47 -1.90 2.53 -1.43 2.97
BC007300 CHC1 chromosome condensation 1 -2,47 -1.66 -2.78 -1.81 1.70
NM_139160 DEPDC7 DEP domain containing 7 -2,46 -1.07 -3.07 -1.15 2.66
NM_015419 DKFZp564I19
22
adlican 2,45 -2.51 3.54 1.82 1.96
M55905 ME2 malic enzyme 2, NAD(+)-dependent, mitochondrial -2,41 -2.10 -3.72 -1.53 2.20
NM_017744 ST7L suppression of tumorigenicity 7 like -2,33 -1.56 -2.11 -1.28 1.54
Z-cut is derived from BAMarray. Fold change; expression in fold change using medians of each group as compared to normal colonic tissue. Gene symbols in bold denote genes which are most dysregulated 
in the carcinomatosis cell line IS3, as compared to IS1 and IS2.
Molecular Cancer 2007, 6:2 http://www.molecular-cancer.com/content/6/1/2
Page 5 of 16
(page number not for citation purposes)
Cluster analysis of differentially expressed genes between primary carcinomas, liver metastases and carcinomatosesFigure 2
Cluster analysis of differentially expressed genes between primary carcinomas, liver metastases and carcinom-
atoses. A) PCA of the 53 most statistical differentially expressed genes between of primary carcinomas (n = 18, black), liver 
metastases (n = 4, blue), and carcinomatoses (n = 4, pink) expressed over three-fold derived from BAMarray. B) HCA of the 
same genes, with the same color coding. Genes are colored based on association to tumor site.
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Table 3: Genes (n = 20), located to chromosome arm 5p that are upregulated in carcinomatoses.
Genebank Acc Gene Symbol Gene Name Fold change 
carcinomatoses
Fold change liver Folde change 
primary
Fold change 
carcinomatoses 
as compared to 
liver and primary
L28175 PTGER4 Prostaglandin E receptor 4 
(subtype EP4)
1.02 -4.41 -2.03 4.24
AK024116 FLJ14054 Hypothetical protein 
FLJ14054
1.20 -2.06 -3.46 3.96
AB061834 RPL37 Ribosomal protein L37 3.62 -1.02 1.04 3.61
BC000518 BASP1 Brain abundant, membrane 
attached signal protein 1
1.18 -1.96 -1.65 2.98
AF155135 RAI14 Retinoic acid induced 14 1.78 -1.35 -1.02 2.96
AF064876 HCN1 Hyperpolarization 
activated cyclic nucleotide-
gated potassium channel 1
1.53 -1.31 -1.18 2.77
AK001989 FLJ11127 Hypothetical protein 
FLJ11127
1.25 -1.16 -1.52 2.58
BC008752 ZNF622 Zinc finger protein 622 1.29 -1.36 -1.05 2.49
AB020647 FBXL7 F-box and leucine-rich 
repeat protein 7
1.43 -1.03 -1.09 2.49
AK025310 FLJ21657 Hypothetical protein 
FLJ21657
1.07 -1.62 -1.15 2.45
U28043 SLC9A3 Solute carrier family 9 
(sodium/hydrogen 
exchanger), isoform 3
1.01 -1.45 -1.39 2.43
BC001380 SDHA Succinate dehydrogenase 
complex, subunit A, 
flavoprotein (Fp)
1.34 -1.04 -1.05 2.39
AF338650 PDZK3 PDZ domain containing 3 1.02 -1.68 -1.02 2.37
AB019494 NIPBL Nipped-B homolog 
(Drosophila)
1.28 -1.13 -1.03 2.36
AF009301 MARCH-VI Membrane-associated 
RING-CH protein VI
1.15 -1.32 -1.06 2.34
BC022339 PC4 Activated RNA polymerase 
II transcription cofactor 4
1.12 -1.28 -1.07 2.30
BC003353 MGC5309 Hypothetical protein 
MGC5309
1.15 -1.18 -1.08 2.27
AF189011 RNASE3L Nuclear RNase III Drosha 1.04 -1.35 -1.07 2.26
BC017586 MGC26610 Hypothetical protein 
MGC26610
1.17 -1.08 -1.06 2.24
AY029177 SKP2 S-phase kinase-associated 
protein 2 (p45)
1.04 -1.00 -1.07 2.08
Ratios; expression in fold change using medians of each group as compared to normal colonic tissue. Fold change carcinomatoses; expression fold 
in carcinomatoses – (fold in liver metastases + primaries)/2.
Genes in bold are upregulated in the carcinomatoses cell line IS3.
Molecular Cancer 2007, 6:2 http://www.molecular-cancer.com/content/6/1/2We selected five of the genes with different expression lev-
els between metastases and primary carcinomas for exper-
imental validation by real-time RT-PCR. Out of these,
three genes were validated as differentially expressed
between the groups. These were upregulation of TM4SF1
and downregulation of ELAC1 (Figure 3) and CCNE1 in
metastases. CCNE1 had particularly low expression in the
carcinomatosis group. RT-PCR data of INCENP was only
weakly following the same trend as the microarray data,
whereas validation failed for PIAS2.
Expression profile stratified by TP53 mutation status
Altogether, ten of 26 tumors harbor TP53 mutation in
exons 5–8 (seven of 18 primary carcinomas, two of four
liver metastases, and one of four carcinomatoses; Table 1).
In order to investigate the influence of the TP53 mutation
status on the gene expression signatures, BAMarray analy-
sis was performed on all tumors dependent on TP53
mutation status. A posterior variance between 0.90 and
1.13 were used, and the hundred most differentially
expressed genes (with statistical significance) both in the
tumors with TP53 mutation (absolute Z-cut ranging from
3.49 to 2.41) and from those with wild type TP53 were
chosen (absolute Z-cut 3.64 to 2.24). Among these two
hundred genes, 75 were expressed more than two-fold dif-
ferently between the groups (27 genes with expression
level above 3.0). Of these 33 genes were associated with
tumors harboring TP53 mutation, and 42 genes with
those without [see Additional file 2]. PCA and HCA were
performed on the 75 genes chosen from BAM analysis,
and both analyses show a clear tendency to discriminate
the tumors with TP53 mutation from those without, inde-
pendently of stage [see Additional file 3]. In the same
manner, the mutant TP53 primary tumors (n = 7) have
been analyzed versus the wild type TP53 primary tumors
(n = 11), and the gene lists associated with either group is
overlapping with the ones found for all tumors stratified
by TP53 mutation status.
ELAC1 downregulation in metastasesFigure 3
ELAC1 downregulation in metastases. We used real-time RT-PCR to validate the expression of five genes with altered 
expression in metastases. ELAC1 was validated as a downregulated gene in colorectal cancer, with a particular downregulation 
in the liver metastases and carcinomatoses. Values are here normalized according to values from normal colon mucosa before 
log2-transformation. Red and blue colored circles denote results from individual samples using real time RT-PCR and microar-
ray experiments, respectively. N, normal colon mucosa; P, primary carcinoma; L, liver metastasis; C, carcinomatosis.
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The three cell lines IS1, IS2, and IS3 are derived from a pri-
mary carcinoma, liver metastasis, and carcinomatosis
from the same patient. We have previously shown com-
mon and specific chromosomal changes for each of the
cell lines [27] (Figure 4A). Here, we analyzed the gene
expression profiles for the same cell lines. IS1 had 1553
genes, IS2 had 1503 genes, whereas IS3 had 1448 genes
with an expression level above two-fold as compared to
normal colonic mucosa. Among these genes, 609 genes
were common in all the three cell lines, whereas IS1 and
IS2 share 263 genes, and IS1 and IS3 share 130 genes. IS2
and IS3 share 225 genes with an expression above two-
fold, which might be considered general metastasis genes
independent of site (Figure 4B). Among the genes dysreg-
ulated more than two-fold in the three cell lines, we chose
the 200 most dysregulated genes solely for each cell line.
This resulted in a list of 600 genes associated with the dif-
ferent tumor stages (data not shown).
Comparisons of in vivo tumors with in vitro model
To address whether the cell lines derived from the differ-
ent stages are representative models of in vivo tumors, we
performed hierarchical cluster analysis on the primary car-
cinomas (n = 18), liver metastases (n = 4), and carcinom-
atoses (n = 4), based on the most dysregulated genes
found associated with each cell line [see Additional file 4].
Three of the four liver metastases cluster close to each
other, whereas the carcinomatoses are spread among the
primary tumors.
When comparing the most differentially expressed genes
specific for in vivo tumors (primary carcinomas, liver
metastases, and carcinomatoses; Figure 2) with the in vitro
model, we found that 40 of 59 in vivo specific genes were
regulated in the same direction in both cell lines and solid
tumors. For the genes associated with liver metastasis, 19
of 28 genes were regulated in the same way in IS2. Five of
the 28 genes were as well most dysregulated in IS2 as com-
pared to IS1 and IS3. For the genes associated with carci-
nomatosis, 6 of 8 genes were confirmed in IS3 (2 of 8
genes are most dysregulated in IS3 compared to IS1 and
IS2), and for the genes specific for primary carcinomas, 15
of 17 genes were confirmed in IS1 (4 of 17 genes are most
dysregulated in IS1 compared to IS2 and IS3) (Table 4).
When evaluating the genes associated with carcinomato-
sis from in vivo and in vitro (IS3) models, we found that 20
of the 29 genes defined from the in vivo data had the same
type of alteration also in the cell line model (six of 29
genes were most dysregulated in IS3 compared to IS1 and
IS2; Table 2). Among the upregulated genes on 5p in car-
cinomatoses (in vivo model), four genes showed the same
type of alteration in the carcinomatosis cell line IS3 as
compared to IS1 and IS2 (Table 3).
Discussion
Several studies have investigated the expression profiles of
human tumors taking advantage of the microarray tech-
nology, including some studies of primary colorectal car-
cinomas [16]. Despite the fact that metastases are the
leading cause of CRC deaths, few have investigated the
expression profiles of metastases, and the reports pub-
lished have focused on lymph nodes and liver metastases
from CRC [19-24,28,29]. Using 22k oligo microarrays we
have nearly doubled the number of DNA sequences stud-
ied compared to most previous publications investigating
gene expression levels of CRC metastases [18-21,24]. By
comparing the genetic profile from different tumor stages
of CRC, including primary tumors and two metastatic
sites, liver and peritoneum, we were able to find potential
genes associated with metastasis, which might play an
important role in the metastatic process. By using Baye-
sian ANOVA for microarray [25], we were able to identify
differentially expressed genes associated with the groups
included. This method has its strengths when comparing
more than two groups. Further statistical tools, such as
HCA and PCA, visualize the differences in the gene expres-
sion between the different stages of CRC, as well as
between the two metastatic sites, liver and the peritoneum
(Figures 1 and 2). Tumors from the two metastatic sites
reveal gene expression profiles more closely related to
each other than to the primary carcinomas. We selected
the primary samples in order to obtain a similar represen-
tation from the different topographical sites in colon and
rectum, from patients from the intermediate clinical
groups (Dukes' B and C). Thus, it seems reasonable to
expect that the expression profiles of these are representa-
tive, supporting the findings of distinct profiles of the
metastases.
A general gene expression pattern for metastases
HCA and PCA were used to visualize the different tran-
script levels of 89 genes in primary tumors and metas-
tases. Forty genes in this expression profile were specific
for the metastasis group [see Additional file 1], including
several genes previously reported in relation to cancer
metastasis. Interestingly, most of the genes have not pre-
viously been described in colorectal metastases, and the
genes of particular interest are involved in processes like
apoptosis and cell growth. Among the downregulated
genes are CASP1, ELAC1, INCENP, ME2, and PLA2G2A.
CASP1 has been shown to induce apoptosis, and disrup-
tion of apoptotic pathways is in general an important fac-
tor in tumor development, and downregulation of this
gene has also previously been reported in primary CRCs
[30]. ELAC1, encoding an RNA processing enzyme, is
located on the chromosome band 18q21, which chromo-
somal loss has previously been linked to poor prognosis
in colorectal cancer [31]. The ELAC1 locus was targeted in
a 300 kb homozygous deletion in lung cancer, which alsoPage 8 of 16
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rect chromosome segregation and cytokinesis during
mitosis and complexes with Aurora B kinases [33]. Inhibi-
tion of INCENP is associated with chromosome aneu-
ploidy, and downregulation of this gene might be
important in metastases. Mice lacking expression of
PLA2G2A have revealed increased colonic polyposis, and
although gene mutations is not reported, lack of expres-
sion and sequence losses from this locus (chromosome
band 1p36) are found in human colorectal carcinomas
[34]. Interestingly, TM4SF1, a member of the transmem-
brane 4 superfamily, was upregulated in the metastases
group. This antigen is known to be highly expressed in
several cancer types, including CRC [22,35], and increased
level of TM4SF1 has been associated with development of
metastases and poor clinical outcome in patients with
lung cancer [36].
Genes differentially expressed between primary CRCs and
normal tissue have been reported by several studies [16],
but only few have shown the differences in expression
profiles between primary tumor and lymph node- and
liver metastases. By statistical analyses we found 49 genes
associated with primary carcinomas as compared with
both liver metastases and carcinomatoses [see Additional
file 1]. Among the genes with increased expression were
CDCA7, CXCL1, CXLC2, CXCL3, and LCN2. Cell division
cycle associated 7, CDCA7, upregulated among the pri-
mary carcinomas, is suggested to be involved in neoplastic
transformation as it acts as a direct Myc target gene [37].
The chemokines CXCL1, CXCL2, and CXCL3 also called
GRO oncogenes, are involved in angiogenesis, develop-
ment, and homeostasis. Upregulation of CXCL1
[16,21,38-41] and CXCL3 [42] has previously been
observed in CRCs and other cancer types [43]. LCN2
binds and transports small lipophilic molecules, and is
involved in cell regulation [44]. Additionally, LCN2 acts
as a subunit of the MMP-9 that has been observed in
increased levels in tumor cells in the transition from
colonic adenomas to carcinomas [45]. Among the down-
regulated genes in primary carcinomas were AKR1B10,
CD36, and LMNB1. The expression of aldo-keto reductase
(AKR1B10) and collagen receptor CD36 is highly reduced
in the primary group, and is previously reported downreg-
ulated in CRCs [46]. LMNB1 belongs to the lamin family,
where the proteins are involved in nuclear stability, chro-
Genome and transcriptome profiles of cell line modelFigure 4
Genome and transcriptome profiles of cell line model. A) Genomic changes in three cell lines IS1, IS2, and IS3 from a 
primary carcinoma, its corresponding liver- and peritoneal metastases derived from the same patient. B) Genes expressed in 
fold change above 2.0 in the same cell lines. 609 genes are found in common between the three cell lines, whereas 263 genes 
are shared between IS1 and IS2, 130 genes in common between IS1 and IS3, and 225 genes are shared between the metastases 
cell lines, IS2 and IS3. 551- (IS1), 406- (IS2), and 484 genes (IS3) are only seen in one cell line.
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Table 4: Genes in common among in vivo tumors and in vitro cell lines.
Genebank Acc. Gene Symbol Gene Name Z-cut Stage Fold change IS1 Fold change IS2 Fold change IS3
X78947 CTGF connective tissue growth factor 2,65 C 1.11 1.59
AF067817 VAV3 vav 3 oncogene -2,63 C -24.77 -3.89 -1.23
AL834404 NETO2 neuropilin (NRP) and tolloid (TLL)-like 2 -2,59 C 1.82 1.21 -12.01
NM_016234 ACSL5 acyl-CoA synthetase long-chain family member 5 -2,52 C -4.64 -1.75 -3.09
NM_139160 LOC91614 novel 58.3 KDA protein -2,46 C -2.23 -1.59 2.58
M55905 ME2 malic enzyme 2, NAD(+)-dependent, mitochondrial -2,41 C 1.21 -1.80 -1.66
NM_000620 NOS1 nitric oxide synthase 1 (neuronal) 4,15 L 2.06 2.51 -1.69
NM_013317 T1A-2 lung type-I cell membrane-associated glycoprotein -3,95 L -9.86 -12.64 -2.37
AK097373 CYP4Z2P cytochrome P450 4Z2 pseudogene 3,92 L 1.78 1.19 -15.97
X98311 CEACAM7 carcinoembryonic antigen-related cell adhesion molecule 7 3,92 L 1.59 1.41 -7.00
NM_139284 LGI4 leucine-rich repeat LGI family, member 4 3,86 L 2.12 1.55 -3.53
AF227137 TAS2R13 taste receptor, type 2, member 13 3,81 L 1.35 1.20 5.73
K00422 HP haptoglobin 3,70 L 1.32 1.33 1.64
NM_001848 COL6A1 collagen, type VI, alpha 1 -3,62 L -5.51 -39.77 -1.60
X04898 APOA2 apolipoprotein A-II 3,57 L 7.16 5.61 -1.18
BC016147 NR4A1 nuclear receptor subfamily 4, group A, member 1 -3,41 L -6.69 -3.26 -6.91
NM_173650 DNAJC5G DnaJ (Hsp40) homolog, subfamily C, member 5 gamma 3,37 L 2.20 2.70 -3.42
NM_152576 MGC24103 hypothetical protein MGC24103 -3,36 L -9.78 -14.62 -1.10
AK056254 KRT4 keratin 4 3,36 L 2.17 1.34 -8.59
NM_004671 PIAS2 protein inhibitor of activated STAT, 2 3,29 L 1.96 1.19 2.16
AF328788 AMN amnionless homolog (mouse) 3,12 L 2.44 3.06 -6.08
BC007287 ZNF213 zinc finger protein 213 3,07 L 3.11 1.81 -2.05
BC012125 SLC39A8 solute carrier family 39 (zinc transporter), member 8 -3,04 L -4.10 -2.34 2.97
NM_020249 ADAMTS9 a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 9 -2,98 L 1.03 -1.45 -2.91
M60828 FGF7 fibroblast growth factor 7 (keratinocyte growth factor) -2,95 L -7.06 -8.61 -15.00
M98398 CD36 CD36 antigen (collagen type I receptor, thrombospondin receptor) -3,17 P -23.00 -21.88 1.11
NM_033201 BC008967 hypothetical gene BC008967 -2,95 P -7.38 -4.64 -2.15
BC001634 VAMP8 vesicle-associated membrane protein 8 (endobrevin) -2,78 P -1.78 -2.89 2.65
NM_022912 C2orf23 chromosome 2 open reading frame 23 -2,72 P -4.00 -7.64 1.80
M27110 PLP1 proteolipid protein 1 (Pelizaeus-Merzbacher disease, spastic paraplegia 2, uncomplicated) -2,67 P -3.05 -4.03 1.94
AB038518 COLEC12 collectin sub-family member 12 -2,62 P -9.65 -9.96 -10.22
AB020629 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 -2,60 P -1.85 -2.07 -6.80
Y12653 UBD ubiquitin D 2,60 P 2.07 1.72 1.35
AK025416 UGCGL1 UDP-glucose ceramide glucosyltransferase-like 1 -2,60 P -5.63 -3.92 1.81
AK021429 SH3MD2 SH3 multiple domains 2 -2,59 P -1.07 -1.26 2.22
NM_032727 INA internexin neuronal intermediate filament protein, alpha -2,54 P -2.19 -2.48 -1.06
AK074207 SLC37A2 solute carrier family 37 (glycerol-3-phosphate transporter), member 2 -2,50 P -2.68 -2.25 1.38
AJ001014 RAMP1 receptor (calcitonin) activity modifying protein 1 -2,46 P -6.00 -4.48 -44.44
AB007895 FLJ11383 hypothetical protein FLJ11383 -2,41 P -1.11 1.09 2.92
NM_016397 TH1L TH1-like (Drosophila) 2,40 P 2.39 2.35 -1.27
Z-cut is derived from BAMarray., L; liver metastases, C; carcinomatoses, P; primary carcinomas Fold change; expression in fold change as compared to normal colonic tissue. Genes shown in bold are most 
dysregulated in the corresponding cell line when compared to solid tumors.
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have been seen in several cancer types, including CRC
[47].
Genes associated with liver metastases
By using BAMarray on expression profiles of liver metas-
tases, in comparison with primary carcinomas and carci-
nomatoses, we identified the most statistically significant
genes associated with liver metastases (Figure 2B). These
genes might play a significant role in the metastasis to the
liver. Several interesting genes were found downregulated,
such as ADAMTS9 and COL6A1 in the liver metastasis
group. ADAMTS9, a thrombospondin metalloproteinase,
is a member of the ADAM-TS family, which controls organ
shape during development, inhibit angiogenesis, and are
implicated in cancer [48,49]. Recently, we have found
another gene in the same family, ADAMTS1, to be a novel
candidate for epigenetic inactivation by promoter hyper-
methylation in colorectal carcinomas [50]. COL6A1
belongs to a collagen family, and are previously reported
upregulated in metastases from medulloblastoma and
cancers of the breast and prostate [11]. Carcinoembryonic
antigen-related cell adhesion molecule 7 (CEACAM7) is
expressed in normal colon, but reported downregulated
in adenomas and colorectal carcinomas [42,51]. Contro-
versially, we found CEACAM7 upregulated in the liver
metastases, suggesting another function in the metastatic
tumors. Another gene with increased expression in liver
metastases of particular interest was PIAS2. Protein inhib-
itor of activated STAT2 (PIAS2) is a transcription factor
controlling cell cycle arrest after DNA damage through
various cellular pathways [52], such as STAT-, MYC- and
TP53 pathways, as transcriptional coregulators [53,54].
The conflicting RT-PCR and microarray data for PIAS2
may be due to their targeting of different mRNA splice var-
iants. The PIAS2 microarray probe targets the exon-exon
junction 12–13, whereas the RT-PCR primers target the
exon-exon junction 5–6 of the transcript.
Genes associated with peritoneal carcinomatoses
To our knowledge, only one molecular genetic study has
previously been performed on carcinomatoses from
colorectal cancer [26], and for the first time, carcinoma-
toses are investigated at the gene expression level. By using
Bayesian ANOVA statistics we identified a gene pattern
associated with carcinomatoses (Table 2, Figure 2). Of the
29 genes expressed above two-fold in the carcinomatosis
group compared to primary carcinomas and liver metas-
tases, several of the genes found were of interest in rela-
tion to cancer biology, such as the upregulation of
DKFZp564I1922 (alias adlican), and CTGF, and the
reduced expression of CCNE1, CHC1, and MYOHD1. The
gene encoding the hypothetical protein adlican is previ-
ously seen highly expressed in colorectal cancer compared
to normal tissue [39]. Expression studies of primary CRCs
have observed dysregulation of several collagens
[16,40,55-57]. CTGF is a connective tissue growth factor
that promotes proliferation, and seems to play an impor-
tant role in the metastatic process, as this gene has been
associated with tumor progression in several types of can-
cer [58-61]. However, the expression of CTGF seems to
play a varying role in several cancer metastases, as expres-
sion of this gene is also reported as a factor for better prog-
nosis by suppression of tumor growth [62]. CCNE1 is an
important component in the cell cycle regulation, and as
a target in the carcinogenesis, overexpression over cyclin E
has been observed in several tumor types [63-65]. How-
ever, decrease of CCNE1 from primary colorectal carcino-
mas to liver metastases is seen, and reduction of cyclin E
in primary carcinomas is associated with poor prognosis
and metastasis to the peritoneum [66]. This is in line with
our observation, as CCNE1 showed a reduced expression
level in peritoneal carcinomatoses compared to primary
tumors. CHC1 is located at chromosome band 1p36 that
is commonly deleted in CRC [67]. It binds to chromatin
and is involved in the regulation of onset of chromosome
condensation [68], thus reduced expression of this gene
might lead to failure in the chromosome segregation. Sev-
eral myosin genes are previously associated with metasta-
sis [11], and interestingly, myosin head domain
(MYOHD1) is found dysregulated in carcinomatoses and
liver metastases in the present dataset.
By using genomic profiling techniques on different stages
of the CRC progression, we have previously identified
gain of 5p by DNA copy number alterations to be specific
for the metastatic process to peritoneal cavity [26,27]. In
this chromosomal region we found 20 genes upregulated
in carcinomatoses as compared to the other stages (more
than two-fold; Table 3), including FBXL7, PTGER4, SKP2,
and ZNF622.
TP53 gene profile
By using BAMarray, we distinguished the expression pat-
tern of the tumors according to their TP53 mutation sta-
tus. Mutations in TP53 are one of the most frequently
encountered genetic alterations in human solid tumors.
More than half of all primary CRCs carry a mutation
within this gene, and inactivation of TP53 is believed to
play a central role in the genetic tumor progression model
[69]. Interestingly, there seem to be differences in the
genetic pattern in tumors revealing mutation from those
with wild type TP53 across the tumor stages [see Addi-
tional files 2 and 3], supporting the importance of TP53
mutation independent of CRC stage. Additionally, the
same pattern is observed in the primary colorectal carci-
nomas. A similar pattern has been observed in breast car-
cinomas as tumors with TP53 mutation show a different
gene expression profile than those without [70]. Taken
together, these observations suggested that inactivation ofPage 11 of 16
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the downstream genes.
Comparison of in vitro models with in vivo tumors
The gene expression variations in the cell line model rep-
resenting three different tumor stages: primary carcino-
mas, liver metastasis, and peritoneal metastasis from the
same patient, provide clues to the understanding of the
cancer progression process (Figure 4) [27]. We arranged
the solid tumors by hierarchical clustering based on genes
derived from the cell line model [see Additional file 4].
The in vivo tumors are on the dendrogram partly posi-
tioned into correct stages, but not as successfully as by
using the genes derived from the in vivo tumors them-
selves (Figure 2). Comparisons of the genetic patterns
derived from analyses of the in vivo tumors with corre-
sponding expression patterns from the cell line model
reveal analogous expression changes of many genes, and
thus strengthen our findings in the solid tumors (Tables 2,
3, and 4). However, the relationship between cell lines
and in vivo tumors based on gene expression should be
handled with caution. Comparisons of gene expression
patterns in cell lines compared to their corresponding
tumor tissue reveal similarities, and cell lines are thought
to reflect the molecular signatures of the tissue from
which the cell lines originated. Nevertheless, it has been
shown that clustering algorithms separate cell lines from
the in vivo tumors of the same cancer disease [71,72].
Conclusion
By studying the gene expression of primary colorectal car-
cinomas, liver metastases and carcinomatoses, we were
able to identify genetic patterns associated with each of
the different stages. We emphasize the importance of the
genetic profiles, where the combination of several genes is
the key feature that is associated with the different stages
of CRC. Several interesting candidate genes representing
potentially therapeutic targets are found in the present
data set. Validation of gene expression signatures in larger
series needs to be performed to improve the understand-
ing of the metastatic process of CRC further.
Materials and methods
Material
Altogether, 29 tissue samples were included in this study;
three of these were from normal colon, eighteen primary
colorectal carcinomas (14 Dukes' B and four Dukes' C; 8
from the right side of colon, 5 from the left side, and 5
from rectum), four liver metastases, and four peritoneal
metastases (carcinomatoses). In addition, as an in vitro
model for cancer progression, three cell lines derived from
tumor samples of the same patient were included (Table
1). These were Isreco1 (IS1) from a primary carcinoma,
Isreco2 (IS2) from a liver metastasis, and Isreco3 (IS3)
from a peritoneal metastasis [27,73]. The cell lines were
kindly provided by Richard Hamelin, INSERM, Paris,
France. The normal colon samples from three patients
with colorectal cancer were taken in a distance from the
tumor sites. Microscopic evaluation of tissue sections
stained by haematoxylin and eosin confirmed that the
normal samples did not contain any tumor cells. For the
primary carcinomas the median age at diagnosis was 75.5
years (range 58 – 88 years), and the median survival time
for these patients was 116 months (range 13 – 147
months). The median age for patients with liver metas-
tases was 71 years (range 55 – 75) with a median survival
of 27 months (range 11 – 93). The median age for patients
with carcinomatoses was 64.5 years (range 40 – 72) with
a median survival at 28 months (range 19 – 65). The series
consisted of 8 females and 18 males. Frozen sections were
taken from all samples prior to RNA extraction, haema-
toxylin and eosin stained, and examined by a pathologist.
All tumors were confirmed carcinomas and visually esti-
mated to contain at least 40% tumor cells; for primaries
the median was 70% (range: 40–90%) for liver metastases
the median was 55% (range: 50–60%), and for the carci-
nomatoses 80% (range: 60–80%). The samples are taken
from a research bio-bank registered at the National Health
Institute and the project is approved by The Norwegian
Data Inspectorate according to the national legislation.
TP53 mutation status
DNA was extracted from tumor tissue pieces neighboring
the ones used for RNA extraction (se below). All tumor
samples were previously analyzed for TP53 mutations
within exons 5–8 by screening for aberrantly migrating
PCR fragments in constant denaturing gradient gel elec-
trophoresis followed by identification of the specific
mutations by direct sequencing (primary tumors, [31];
metastases, unpublished data).
Total RNA extraction
The tissues were ground in liquid nitrogen and homoge-
nized with a pellet pestle motor in 1ml of Trizol (Invitro-
gen, Carlsbad, CA). 0.2 ml of chloroform was added and
the samples were vigorously shaken for 20s, and then
incubated at RT for 5 min. After centrifugation at 12,000
× g for 15 min, the aqueous phase was mixed with 0.5 ml
isopropanol. The RNA was allowed to precipitate for 10
min and collected after centrifugation at 12,000 × g for 10
min at 4°C. The RNA pellet was washed with 75% etha-
nol, collected after a brief centrifugation, air dried, and re-
suspended in H2O at 55°C in 10 min. The purified RNA
was quantified by spectrophotometer (NanoDrop 1000,
NanoDrop Technologies, Boston, MA), and the quality
was evaluated by capillary electrophoresis (Agilent 2100
Bioanalyzer, Agilent Technologies, Palo Alto, CA).Page 12 of 16
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For each of the test and reference samples, 20 µg total RNA
was reversely transcribed using the Agilent direct-label
cDNA synthesis kit (Agilent Technologies) according to
the manufacturer's directions. As a common reference for
all samples, we used the "Universal Human Reference
RNA", containing mRNA from ten cancer cell lines (Strat-
agene, La Jolla, CA). cDNA was labeled with cyanine 5-
dCTP for test samples and cyanine 3-dCTP for the com-
mon reference (PerkinElmer Life Science, Boston, MA),
and was purified using QIAquick PCR Purification col-
umns (Qiagen, Valencia, CA). The cDNA was suspended
in hybridization buffer and hybridized to Agilent Human
1A v2 22 k oligo microarrays (Agilent Technologies) for
17 h at 60°C according to the Agilent protocol. The slides
were scanned by a laser confocal scanner (Agilent Tech-
nologies).
Microarray data analyses
The image processing was performed with Agilent Feature
Extraction 7.5 (Agilent Technologies). Local background
subtraction and linear/LOWESS normalization were per-
formed. Semi-processed values were imported into BASE
(BioArray Software Environment; [74] customized for
Agilent microarrays by the Norwegian Microarray Consor-
tium), where spots with inadequate measurements were
flagged and ratios calculated. Oligonucleotide probes
with inadequate measurements in more than five of the
29 tumor samples were excluded from the analyses. For
further analyses, we used data corresponding to 18 264
unique gene bank accession numbers, represented by 16
553 unique gene symbols [75].
BAMarray 2.0 (Bayesian ANOVA Analyses of Variation of
Microarrays) [25] was used with default settings for
detecting differentially expressed genes between two or
more groups. BAMarray uses shrinkage estimation com-
bined with model averaging. This provides a good balance
between false rejection (the total number of genes falsely
identified as being differentially expressed) and false non-
rejections (the total number of genes falsely identified as
being non-differentially expressed). By combing Z-cut
and posterior variances from Bayesian ANOVA for micro-
array, we are likely to identify the differentially expressed
target genes. Missing values were estimated in J-Express
Pro 2.6 [76] with k-nearest neighbor imputation (k = 10).
The most statistically significant genes associated with
each group were reported with normal colon mucosa as
the "baseline group".
Principal component analysis (PCA) and hierarchical
cluster analysis (HCA) were performed in J-Express Pro
2.6 [76]. PCA reduces the dimensionality and detects
structure in the relationships among variables (classify
variables) [77]. HCA by use of average-linkage and Eucli-
dean distance similarity measure was used to arrange var-
iables according to groups based on their similarity.
Afterwards, the results were visualized in a dendrogram.
For each gene, expression values in tumor samples were
centered over the median expression of the normal colon
epithelial tissues before clustering.
Quantitative real-time gene expression analyses
The mRNA expression of five potential target genes,
CCNE1, ELAC1, INCENP, PIAS2, and TM4SF1, was meas-
ured by quantitative real-time fluorescence detection
using TaqMan 7900 HT (Applied Biosystems, Foster City,
CA). For each sample, cDNA was generated from five µg
total RNA using a high capacity cDNA archive kit (Applied
Biosystems) following the manufacturers' protocol. Ten
ng cDNA was amplified for each gene using pre-designed
assays (Hs00233356_m1, Hs00218846_m1,
Hs00220336_m1, Hs00190699_m1, and
Hs00371997_m1, respectively; Applied Biosystems). All
samples were amplified in triplicates and the quantitative
expression levels were measured against a standard curve
generated from dilutions of cDNA from the human uni-
versal reference RNA (containing a mixture of RNA from
ten different cell lines; Stratagene, CA). The median
expression value of each sample was normalized against
the average of the median of two endogenous controls,
ACTB (4352935E; Applied Biosystems) and GUSB
(4333767F; Applied Biosystems).
Authors' contributions
KK carried the microarray experimental work, performed
the statistical analyses, interpreted the results, and drafted
the manuscript.
GEL performed RT-PCR experimental validation and par-
ticipated in scientific discussions and manuscript prepara-
tion.
CBD participated in the statistical analyses and in the
manuscript preparation.
LTB were responsible for the TP53 mutation analysis and
participated in the study design.
GIM, JNM, TOR, KEG were responsible for referring the
patients, collecting tissue specimens and for clinical infor-
mation.
JNM re-examined all histological diagnoses and indicated
representative tumor areas present in frozen sections
taken from samples used for RNA extraction.
OM participated in scientific discussions and in the man-
uscript preparation.Page 13 of 16
(page number not for citation purposes)
Molecular Cancer 2007, 6:2 http://www.molecular-cancer.com/content/6/1/2RIS participated in statistical analysis, evaluation of data,
and in the manuscript preparation.
RAL conceived the study, was responsible for its design
and coordination and participated in evaluation of the
data and in the manuscript preparation.
All authors have read and approved the final version of
the manuscript.
Additional material
References
1. The Cancer Registry of Norway   [http://www.kreftregis
teret.no]. Accessed 2006.
2. Potter JD: Colorectal cancer: molecules and populations.  J
Natl Cancer Inst 1999, 91:916-932.
3. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitor-
ing of gene expression patterns with a complementary DNA
microarray.  Science 1995, 270:467-470.
4. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR,
Vogelstein B, Kinzler KW: Gene expression profiles in normal
and cancer cells.  Science 1997, 276:1268-1272.
5. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack
JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A,
Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Bot-
stein D: Molecular portraits of human breast tumors.  Nature
2000, 406:747-752.
6. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Rad-
macher M, Simon R, Yakhini Z, Ben Dor A, Sampas N, Dougherty E,
Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P,
Carpten J, Gillanders E, et al.: Molecular classification of cutane-
ous malignant melanoma by gene expression profiling.
Nature 2000, 406:536-540.
7. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D,
Butterfoss D, Xiang D, Zanation A, Yin X, Shockley WW, Weissler
MC, Dressler LG, Shores CG, Yarbrough WG, Perou CM: Molecu-
lar classification of head and neck squamous cell carcinomas
using patterns of gene expression.  Cancer Cell 2004, 5:489-500.
8. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, Schultz
PG, Powell SM, Moskaluk CA, Frierson HF Jr, Hampton GM: Molec-
ular classification of human carcinomas by use of gene
expression signatures.  Cancer Res 2001, 61:7388-7393.
9. 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse
HL, van der KK, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven
RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression
profiling predicts clinical outcome of breast cancer.  Nature
2002, 415:530-536.
10. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie
T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC,
Brown PO, Botstein D, Eystein LP, Borresen-Dale AL: Gene expres-
sion patterns of breast carcinomas distinguish tumor sub-
classes with clinical implications.  Proc Natl Acad Sci USA 2001,
98:10869-10874.
11. Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signa-
ture of metastasis in primary solid tumors.  Nat Genet 2003,
33:49-54.
12. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE,
Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Haya-
saka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S: Gene-
expression profiles predict survival of patients with lung ade-
nocarcinoma.  Nat Med 2002, 8:816-824.
13. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL:
Gene expression profiling predicts clinical outcome of pros-
tate cancer.  J Clin Invest 2004, 113:913-923.
14. Weiss MM, Kuipers EJ, Postma C, Snijders AM, Siccama I, Pinkel D,
Westerga J, Meuwissen SG, Albertson DG, Meijer GA: Genomic
profiling of gastric cancer predicts lymph node status and
survival.  Oncogene 2003, 22:1872-1879.
15. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M,
McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC,
Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T,
Mukherjee S, Rifkin R, Califano A, et al.: Prediction of central nerv-
ous system embryonal tumor outcome based on gene
expression.  Nature 2002, 415:436-442.
16. Shih W, Chetty R, Tsao MS: Expression profiling by microarrays
in colorectal cancer (Review).  Oncol Rep 2005, 13:517-524.
17. Buckhaults P, Rago C, St Croix B, Romans KE, Saha S, Zhang L, Vogel-
stein B, Kinzler KW: Secreted and cell surface genes expressed
in benign and malignant colorectal tumors.  Cancer Res 2001,
61:6996-7001.
18. Kitahara O, Furukawa Y, Tanaka T, Kihara C, Ono K, Yanagawa R,
Nita ME, Takagi T, Nakamura Y, Tsunoda T: Alterations of gene
expression during colorectal carcinogenesis revealed by
cDNA microarrays after laser-capture microdissection of
tumor tissues and normal epithelia.  Cancer Res 2001,
61:3544-3549.
19. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M,
Cantor A, Coppola D, Yeatman TJ: Osteopontin identified as lead
marker of colon cancer progression, using pooled sample
expression profiling.  J Natl Cancer Inst 2002, 94:513-521.
20. Koehler A, Bataille F, Schmid C, Ruemmele P, Waldeck A, Blaszyk H,
Hartmann A, Hofstaedter F, Dietmaier W: Gene expression pro-
filing of colorectal cancer and metastases divides tumors
according to their clinicopathological stage.  J Pathol 2004,
204:65-74.
21. Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C,
Charafe-Jauffret E, Loriod B, Bachelart L, Montfort J, Victorero G,
Viret F, Ollendorff V, Fert V, Giovaninni M, Delpero JR, Nguyen C,
Additional file 1
List of 89 genes differentially expressed between primary and metastatic 
tumors.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-6-2-S1.pdf]
Additional file 2
List of 75 genes differentially expressed between tumors with or without 
mutated TP53.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-6-2-S2.pdf]
Additional file 3
Principal components and hierarchical clustering analyses of differentially 
expressed genes in colorectal carcinomas stratified by TP53 mutation sta-
tus. A) Principal components analysis of 75 genes differentially expressed, 
assessed by BAMarray, in colorectal carcinomas stratified by TP53 muta-
tion status. Red circles represent tumors with TP53 mutation, whereas 
black circles are wild type tumors. B) Dendrogram from hierarchical clus-
tering analysis performed for the same genes (color-coding as in A).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-6-2-S3.pdf]
Additional file 4
Tumor clustering based on genes derived from cell lines modeling the 
metastasis process. Dendrogram from hierarchical clustering analysis of a 
panel of primary carcinomas (n = 18), liver metastases (n = 4), and car-
cinomatoses (n = 4), on genes associated with cell lines derived from 
tumors with different metastatic status.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-6-2-S4.pdf]Page 14 of 16
(page number not for citation purposes)
Molecular Cancer 2007, 6:2 http://www.molecular-cancer.com/content/6/1/2Viens P, Monges G, Birnbaum D, et al.: Gene expression profiling
of colon cancer by DNA microarrays and correlation with
histoclinical parameters.  Oncogene 2004, 23:1377-1391.
22. Bandres E, Catalan V, Sola I, Honorato B, Cubedo E, Cordeu L,
Andion E, Escalada A, Zarate R, Salgado E, Zabalegui N, Garcia F, Gar-
cia-Foncillas J: Dysregulation of apoptosis is a major mecha-
nism in the lymph node involvement in colorectal
carcinoma.  Oncol Rep 2004, 12:287-292.
23. Li M, Lin YM, Hasegawa S, Shimokawa T, Murata K, Kameyama M,
Ishikawa O, Katagiri T, Tsunoda T, Nakamura Y, Furukawa Y: Genes
associated with liver metastasis of colon cancer, identified by
genome-wide cDNA microarray.  Int J Oncol 2004, 24:305-312.
24. D'Arrigo A, Belluco C, Ambrosi A, Digito M, Esposito G, Bertola A,
Fabris M, Nofrate V, Mammano E, Leon A, Nitti D, Lise M: Meta-
static transcriptional pattern revealed by gene expression
profiling in primary colorectal carcinoma.  Int J Cancer 2005,
115:256-262.
25. Ishwaran H, Rao JS: Detecting differentially expressed genes in
microarrays using bayesian model selection.  Journal of the
American Statistical Association 2003, 98:438-455.
26. Diep CB, Teixeira MR, Thorstensen L, Wiig JN, Eknaes M, Nesland
JM, Giercksky KE, Johansson B, Lothe RA: Genome characteristics
of primary carcinomas, local recurrences, carcinomatoses,
and liver metastases from colorectal cancer patients.  Mol
Cancer 2004, 3(6):6.
27. Kleivi K, Teixeira MR, Eknaes M, Diep CB, Jakobsen KS, Hamelin R,
Lothe RA: Genome signatures of colon carcinoma cell lines.
Cancer Genet Cytogenet 2004, 155:119-131.
28. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B,
Romans KE, Choti MA, Lengauer C, Kinzler KW, Vogelstein B: A
phosphatase associated with metastasis of colorectal cancer.
Science 2001, 294:1343-1346.
29. Yanagawa R, Furukawa Y, Tsunoda T, Kitahara O, Kameyama M,
Murata K, Ishikawa O, Nakamura Y: Genome-wide screening of
genes showing altered expression in liver metastases of
human colorectal cancers by cDNA microarray.  Neoplasia
2001, 3:395-401.
30. Jarry A, Vallette G, Cassagnau E, Moreau A, Bou-Hanna C, Lemarre
P, Letessier E, Le Neel JC, Galmiche JP, Laboisse CL: Interleukin 1
and interleukin 1beta converting enzyme (caspase 1) expres-
sion in the human colonic epithelial barrier. Caspase 1 down-
regulation in colon cancer.  Gut 1999, 45:246-251.
31. Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO, Lothe
RA: Genetic tumor markers with prognostic impact in dukes'
stages B and C colorectal cancer patients.  J Clin Oncol 2003,
21:820-829.
32. Yanaihara N, Kohno T, Takakura S, Takei K, Otsuka A, Sunaga N,
Takahashi M, Yamazaki M, Tashiro H, Fukuzumi Y, Fujimori Y, Hagi-
wara K, Tanaka T, Yokota J: Physical and transcriptional map of
a 311-kb segment of chromosome 18q21, a candidate lung
tumor suppressor locus.  Genomics 2001, 72:169-179.
33. Lampson MA, Renduchitala K, Khodjakov A, Kapoor TM: Correct-
ing improper chromosome-spindle attachments during cell
division.  Nat Cell Biol 2004, 6:232-237.
34. Praml C, Amler LC, Dihlmann S, Finke LH, Schlag P, Schwab M:
Secretory type II phospholipase A2 (PLA2G2A) expression
status in colorectal carcinoma derived cell lines and in nor-
mal colonic mucosa.  Oncogene 1998, 17:2009-2012.
35. Marken JS, Schieven GL, Hellstrom I, Hellstrom KE, Aruffo A: Clon-
ing and expression of the tumor-associated antigen L6.  Proc
Natl Acad Sci USA 1992, 89:3503-3507.
36. Kao YR, Shih JY, Wen WC, Ko YP, Chen BM, Chan YL, Chu YW,
Yang PC, Wu CW, Roffler SR: Tumor-associated antigen L6 and
the invasion of human lung cancer cells.  Clin Cancer Res 2003,
9:2807-2816.
37. Prescott JE, Osthus RC, Lee LA, Lewis BC, Shim H, Barrett JF, Guo
Q, Hawkins AL, Griffin CA, Dang CV: A novel c-Myc-responsive
gene, JPO1, participates in neoplastic transformation.  J Biol
Chem 2001, 276:48276-48284.
38. Notterman DA, Alon U, Sierk AJ, Levine AJ: Transcriptional gene
expression profiles of colorectal adenoma, adenocarcinoma,
and normal tissue examined by oligonucleotide arrays.  Can-
cer Res 2001, 61:3124-3130.
39. Zou TT, Selaru FM, Xu Y, Shustova V, Yin J, Mori Y, Shibata D, Sato
F, Wang S, Olaru A, Deacu E, Liu TC, Abraham JM, Meltzer SJ: Appli-
cation of cDNA microarrays to generate a molecular taxon-
omy capable of distinguishing between colon cancer and
normal colon.  Oncogene 2002, 21:4855-4862.
40. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang
C, Fleming J, Tavana D, Frenkel E, Becerra C: Identification and
validation of genes involved in the pathogenesis of colorectal
cancer using cDNA microarrays and RNA interference.  Clin
Cancer Res 2003, 9:931-946.
41. Li A, Varney ML, Singh RK: Constitutive expression of growth
regulated oncogene (gro) in human colon carcinoma cells
with different metastatic potential and its role in regulating
their metastatic phenotype.  Clin Exp Metastasis 2004,
21:571-579.
42. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S,
Laiho P, Aaltonen LA, ORntoft TF: Differential gene expression
in colon cancer of the caecum versus the sigmoid and rectos-
igmoid.  Gut 2005, 54:374-384.
43. Yang SK, Choi MS, Kim OH, Myung SJ, Jung HY, Hong WS, Kim JH,
Min YI: The increased expression of an array of C-X-C and C-
C chemokines in the colonic mucosa of patients with ulcera-
tive colitis: regulation by corticosteroids.  Am J Gastroenterol
2002, 97:126-132.
44. Friedl A, Stoesz SP, Buckley P, Gould MN: Neutrophil gelatinase-
associated lipocalin in normal and neoplastic human tissues.
Cell type-specific pattern of expression.  Histochem J 1999,
31:433-441.
45. Zucker S, Vacirca J: Role of matrix metalloproteinases (MMPs)
in colorectal cancer.  Cancer Metastasis Rev 2004, 23:101-117.
46. Croner RS, Foertsch T, Brueckl WM, Guenther K, Siebenhaar R,
Stremmel C, Matzel KE, Papadopoulos T, Kirchner T, Behrens J,
Klein-Hitpass L, Stuerzl M, Hohenberger W, Reingruber B: Com-
mon denominator genes that distinguish colorectal carci-
noma from normal mucosa.  Int J Colorectal Dis 2005, 20:353-362.
47. Moss SF, Krivosheyev V, de Souza A, Chin K, Gaetz HP, Chaudhary
N, Worman HJ, Holt PR: Decreased and aberrant nuclear lamin
expression in gastrointestinal tract neoplasms.  Gut 1999,
45:723-729.
48. Clark ME, Kelner GS, Turbeville LA, Boyer A, Arden KC, Maki RA:
ADAMTS9, a novel member of the ADAM-TS/metallospon-
din gene family.  Genomics 2000, 67:343-350.
49. Porter S, Clark IM, Kevorkian L, Edwards DR: The ADAMTS met-
alloproteinases.  Biochem J 2005, 386:15-27.
50. Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum
T, Lothe RA: ADAMTS1, CRABP1, and NR3C1 identified as epi-
genetically deregulated genes in colorectal tumorigenesis.
Cell Oncol 2006, 28:259-272.
51. Thompson J, Seitz M, Chastre E, Ditter M, Aldrian C, Gespach C,
Zimmermann W: Down-regulation of carcinoembryonic anti-
gen family member 2 expression is an early event in colorec-
tal tumorigenesis.  Cancer Res 1997, 57:1776-1784.
52. Wanzel M, Kleine-Kohlbrecher D, Herold S, Hock A, Berns K, Park J,
Hemmings B, Eilers M: Akt and 14-3-3eta regulate Miz1 to con-
trol cell-cycle arrest after DNA damage.  Nat Cell Biol 2005,
7:30-41.
53. Wu S, Cetinkaya C, Munoz-Alonso MJ, von der LN, Bahram F, Beuger
V, Eilers M, Leon J, Larsson LG: Myc represses differentiation-
induced p21CIP1 expression via Miz-1-dependent interac-
tion with the p21 core promoter.  Oncogene 2003, 22:351-360.
54. Schmidt D, Muller S: Members of the PIAS family act as SUMO
ligases for c-Jun and p53 and repress p53 activity.  Proc Natl
Acad Sci USA 2002, 99:2872-2877.
55. Komori T, Takemasa I, Higuchi H, Yamasaki M, Ikeda M, Yamamoto
H, Ohue M, Nakamori S, Sekimoto M, Matsubara K, Monden M: Iden-
tification of differentially expressed genes involved in color-
ectal carcinogenesis using a cDNA microarray.  J Exp Clin
Cancer Res 2004, 23:521-527.
56. Mori Y, Selaru FM, Sato F, Yin J, Simms LA, Xu Y, Olaru A, Deacu E,
Wang S, Taylor JM, Young J, Leggett B, Jass JR, Abraham JM, Shibata
D, Meltzer SJ: The impact of microsatellite instability on the
molecular phenotype of colorectal tumors.  Cancer Res 2003,
63:4577-4582.
57. Dunican DS, McWilliam P, Tighe O, Parle-McDermott A, Croke DT:
Gene expression differences between the microsatellite
instability (MIN) and chromosomal instability (CIN) pheno-
types in colorectal cancer revealed by high-density cDNA
array hybridization.  Oncogene 2002, 21:3253-3257.Page 15 of 16
(page number not for citation purposes)
Molecular Cancer 2007, 6:2 http://www.molecular-cancer.com/content/6/1/2Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
58. Zeng ZJ, Yang LY, Ding X, Wang W: Expressions of cysteine-
rich61, connective tissue growth factor and Nov genes in
hepatocellular carcinoma and their clinical significance.
World J Gastroenterol 2004, 10:3414-3418.
59. Shimizu T, Okayama A, Inoue T, Takeda K: Analysis of gene
expression during staurosporine-induced neuronal differen-
tiation of human prostate cancer cells.  Oncol Rep 2005,
14:441-448.
60. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel
RE: Differential expression of the CCN family members
Cyr61, CTGF and Nov in human breast cancer.  Endocr Relat
Cancer 2004, 11:781-791.
61. Chang CC, Shih JY, Jeng YM, Su JL, Lin BZ, Chen ST, Chau YP, Yang
PC, Kuo ML: Connective tissue growth factor and its role in
lung adenocarcinoma invasion and metastasis.  J Natl Cancer
Inst 2004, 96:364-375.
62. Lin BR, Chang CC, Che TF, Chen ST, Chen RJ, Yang CY, Jeng YM,
Liang JT, Lee PH, Chang KJ, Chau YP, Kuo ML: Connective tissue
growth factor inhibits metastasis and acts as an independent
prognostic marker in colorectal cancer.  Gastroenterology 2005,
128:9-23.
63. Bieche I, Tozlu S, Girault I, Lidereau R: Identification of a three-
gene expression signature of poor-prognosis breast carci-
noma.  Mol Cancer 2004, 3:37.
64. Miller CT, Moy JR, Lin L, Schipper M, Normolle D, Brenner DE, Ian-
nettoni MD, Orringer MB, Beer DG: Gene amplification in
esophageal adenocarcinomas and Barrett's with high-grade
dysplasia.  Clin Cancer Res 2003, 9:4819-4825.
65. Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H, Emi M, Inazawa J:
TFDP1, CUL4A, and CDC16 identified as targets for ampli-
fication at 13q34 in hepatocellular carcinomas.  Hepatology
2002, 35:1476-1484.
66. Li JQ, Miki H, Ohmori M, Wu F, Funamoto Y: Expression of cyclin
E and cyclin-dependent kinase 2 correlates with metastasis
and prognosis in colorectal carcinoma.  Hum Pathol 2001,
32:945-953.
67. Bardi G, Pandis N, Fenger C, Kronborg O, Bomme L, Heim S: Dele-
tion of 1p36 as a primary chromosomal aberration in intes-
tinal tumorigenesis.  Cancer Res 1993, 53:1895-1898.
68. Nishimoto T, Seino H, Seki N, Hori TA: The human CHC1 gene
encoding RCC1 (regulator of chromosome condensation)
(CHC1) is localized to human chromosome 1p36.1.  Genomics
1994, 23:719-721.
69. Fearon ER, Vogelstein B: A genetic model for colorectal tumor-
igenesis.  Cell 1990, 61:759-767.
70. Sørlie T: Molecular portraits of breast cancer: tumor subtypes
as distinct disease entities.  Eur J Cancer 2004, 40:2667-2675.
71. Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, Levine
AJ: Broad patterns of gene expression revealed by clustering
analysis of tumor and normal colon tissues probed by oligo-
nucleotide arrays.  Proc Natl Acad Sci USA 1999, 96:6745-6750.
72. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V,
Jeffrey SS, van de RM, Waltham M, Pergamenschikov A, Lee JC,
Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown
PO: Systematic variation in gene expression patterns in
human cancer cell lines.  Nat Genet 2000, 24:227-235.
73. Cajot JF, Sordat I, Silvestre T, Sordat B: Differential display clon-
ing identifies motility-related protein (MRP1/CD9) as highly
expressed in primary compared to metastatic human colon
carcinoma cells.  Cancer Res 1997, 57:2593-2597.
74. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A,
Peterson C: BioArray Software Environment (BASE): a plat-
form for comprehensive management and analysis of micro-
array data.  Genome Biol 2002, 3:software0003.1-0003.6.
75. TIGR resourerer April 2005  Chromosome locations and cytobands
extracted from Source May 2005  [http://compbio.dfci.harvard.edu/tgi/
cgi-bin/magic/r1.pl]. http://genome-www5.stanford.edu/cgi-bin/
source/sourceSearch
76. Dysvik B, Jonassen I: J-Express: exploring gene expression data
using Java.  Bioinformatics 2001, 17:369-370.
77. Raychaudhuri S, Stuart JM, Altman RB: Principal component anal-
ysis to summarize microarray experiments: application to
sporulation time series.  Pac Symp Biocomput 2002:455-466.Page 16 of 16
(page number not for citation purposes)
